These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31505989)

  • 1. Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells.
    Gerecke C; Schumacher F; Berndzen A; Homann T; Kleuser B
    Epigenetics; 2020 Mar; 15(3):307-322. PubMed ID: 31505989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.
    Müller T; Gessi M; Waha A; Isselstein LJ; Luxen D; Freihoff D; Freihoff J; Becker A; Simon M; Hammes J; Denkhaus D; zur Mühlen A; Pietsch T; Waha A
    Am J Pathol; 2012 Aug; 181(2):675-83. PubMed ID: 22688054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
    Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
    Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1/2 Mutants Inhibit TET-Promoted Oxidation of RNA 5mC to 5hmC.
    Xu Q; Wang K; Wang L; Zhu Y; Zhou G; Xie D; Yang Q
    PLoS One; 2016; 11(8):e0161261. PubMed ID: 27548812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced
    Li T; Cox CD; Ozer BH; Nguyen NT; Nguyen HN; Lai TJ; Li S; Liu F; Kornblum HI; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
    Mol Cancer Res; 2018 Jun; 16(6):947-960. PubMed ID: 29545476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
    Pusch S; Krausert S; Fischer V; Balss J; Ott M; Schrimpf D; Capper D; Sahm F; Eisel J; Beck AC; Jugold M; Eichwald V; Kaulfuss S; Panknin O; Rehwinkel H; Zimmermann K; Hillig RC; Guenther J; Toschi L; Neuhaus R; Haegebart A; Hess-Stumpp H; Bauser M; Wick W; Unterberg A; Herold-Mende C; Platten M; von Deimling A
    Acta Neuropathol; 2017 Apr; 133(4):629-644. PubMed ID: 28124097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascorbate-induced generation of 5-hydroxymethylcytosine is unaffected by varying levels of iron and 2-oxoglutarate.
    Dickson KM; Gustafson CB; Young JI; Züchner S; Wang G
    Biochem Biophys Res Commun; 2013 Oct; 439(4):522-7. PubMed ID: 24021282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.
    Duncan CG; Barwick BG; Jin G; Rago C; Kapoor-Vazirani P; Powell DR; Chi JT; Bigner DD; Vertino PM; Yan H
    Genome Res; 2012 Dec; 22(12):2339-55. PubMed ID: 22899282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
    Molenaar RJ; Botman D; Smits MA; Hira VV; van Lith SA; Stap J; Henneman P; Khurshed M; Lenting K; Mul AN; Dimitrakopoulou D; van Drunen CM; Hoebe RA; Radivoyevitch T; Wilmink JW; Maciejewski JP; Vandertop WP; Leenders WP; Bleeker FE; van Noorden CJ
    Cancer Res; 2015 Nov; 75(22):4790-802. PubMed ID: 26363012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced ten-eleven translocation and isocitrate dehydrogenase expression in inflammatory hidradenitis suppurativa lesions.
    Hessam S; Gambichler T; Skrygan M; Sand M; Rüddel I; Scholl L; Bechara FG
    Eur J Dermatol; 2018 Aug; 28(4):449-456. PubMed ID: 30325321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
    Inoue S; Li WY; Tseng A; Beerman I; Elia AJ; Bendall SC; Lemonnier F; Kron KJ; Cescon DW; Hao Z; Lind EF; Takayama N; Planello AC; Shen SY; Shih AH; Larsen DM; Li Q; Snow BE; Wakeham A; Haight J; Gorrini C; Bassi C; Thu KL; Murakami K; Elford AR; Ueda T; Straley K; Yen KE; Melino G; Cimmino L; Aifantis I; Levine RL; De Carvalho DD; Lupien M; Rossi DJ; Nolan GP; Cairns RA; Mak TW
    Cancer Cell; 2016 Aug; 30(2):337-348. PubMed ID: 27424808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
    Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
    J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Peeters TH; Lenting K; Breukels V; van Lith SAM; van den Heuvel CNAM; Molenaar R; van Rooij A; Wevers R; Span PN; Heerschap A; Leenders WPJ
    Cancer Metab; 2019; 7():4. PubMed ID: 31139406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1.
    Bai X; Zhang H; Zhou Y; Nagaoka K; Meng J; Ji C; Liu D; Dong X; Cao K; Mulla J; Cheng Z; Mueller W; Bay A; Hildebrand G; Lu S; Wallace J; Wands JR; Sun B; Huang CK
    Hepatology; 2021 May; 73(5):1747-1763. PubMed ID: 32740973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles and Regulations of TET Enzymes in Solid Tumors.
    Bray JK; Dawlaty MM; Verma A; Maitra A
    Trends Cancer; 2021 Jul; 7(7):635-646. PubMed ID: 33468438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance.
    Van Damme M; Crompot E; Meuleman N; Maerevoet M; Mineur P; Bron D; Lagneaux L; Stamatopoulos B
    Clin Epigenetics; 2016; 8():132. PubMed ID: 27980696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
    Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
    Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.